Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The role of HLA antibodies in allogeneic SCT: is the ‘type-and-screen’ strategy necessary not only for blood type but also for HLA?

Abstract

The role of HLA antibodies in SCT has drawn increasing attention because of the significantly increased number of patients who receive HLA-mismatched SCT, including cord blood transplantation, haploidentical SCT and unrelated SCT. Technical advancements in the methods of HLA Ab testing have realized rapid, accurate and objective identification, as well as quantification of specific HLA antibodies. Recent clinical studies have suggested that the presence of donor-specific HLA antibodies (DSA) in patients is associated with graft failure in HLA-mismatched SCT when the above-listed stem cell sources are used and results in different impacts. Of note, most of the ‘HLA-matched’ unrelated SCT actually involve HLA mismatches in HLA-DP and the presence of antibodies against this locus has been reported to be associated with graft failure. Thus, HLA Ab should be examined as a work-up for all patients who undergo SCT from ‘alternative donors.’ The simplest route for preventing HLA Ab-mediated graft failure in Ab-positive patients is to avoid donors who possess the target Ag of HLA antibodies. If SCT from such donors must be performed, treatment for DSA before SCT may improve the chances of successful donor engraftment.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Hod E, Schwartz J . Platelet transfusion refractoriness. Br J Haematol 2008; 142: 348–360.

    Article  PubMed  Google Scholar 

  2. Middelburg RA, van Stein D, Briet E, van der Bom JG . The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion 2008; 48: 2167–2176.

    Article  PubMed  Google Scholar 

  3. Reil A, Keller-Stanislawski B, Gunay S, Bux J . Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang 2008; 95: 313–317.

    Article  CAS  PubMed  Google Scholar 

  4. Keller-Stanislawski B, Reil A, Gunay S, Funk MB . Frequency and severity of transfusion-related acute lung injury—German haemovigilance data (2006–2007). Vox Sang 2010; 98: 70–77.

    Article  CAS  PubMed  Google Scholar 

  5. Shaz BH, Stowell SR, Hillyer CD . Transfusion-related acute lung injury: from bedside to bench and back. Blood 2011; 117: 1463–1471.

    Article  CAS  PubMed  Google Scholar 

  6. Barge AJ, Johnson G, Witherspoon R, Torok-Storb B . Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood 1989; 74: 1477–1480.

    CAS  PubMed  Google Scholar 

  7. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197–204.

    Article  CAS  PubMed  Google Scholar 

  8. Patel R, Terasaki PI . Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735–739.

    Article  CAS  PubMed  Google Scholar 

  9. Gebel HM, Bray RA, Nickerson P . Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs risk. Am J Transplant 2003; 3: 1488–1500.

    Article  PubMed  Google Scholar 

  10. Terasaki PI, Cai J . Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 2008; 86: 377–383.

    Article  PubMed  Google Scholar 

  11. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754–1761.

    Article  CAS  PubMed  Google Scholar 

  12. Caro-Oleas JL, Gonzalez-Escribano MF, Gonzalez-Roncero FM, Acevedo-Calado MJ, Cabello-Chaves V, Gentil-Govantes MA et al. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transplant 2012; 27: 1231–1238.

    Article  CAS  PubMed  Google Scholar 

  13. Maslanka K, Michur H, Zupanska B, Uhrynowska M, Nowak J . Leucocyte antibodies in blood donors and a look back on recipients of their blood components. Vox Sang 2007; 92: 247–249.

    Article  CAS  PubMed  Google Scholar 

  14. Powers A, Stowell CP, Dzik WH, Saidman SL, Lee H, Makar RS . Testing only donors with a prior history of pregnancy or transfusion is a logical and cost-effective transfusion-related acute lung injury prevention strategy. Transfusion 2008; 48: 2549–2558.

    Article  PubMed  Google Scholar 

  15. Triulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009; 49: 1825–1835.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, van Dijk BA, van Putten WL, Claas FH et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995; 85: 824–828.

    CAS  PubMed  Google Scholar 

  17. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861–1869.

  18. van de Watering L, Hermans J, Witvliet M, Versteegh M, Brand A . HLA and RBC immunization after filtered and buffy coat-depleted blood transfusion in cardiac surgery: a randomized controlled trial. Transfusion 2003; 43: 765–771.

    Article  PubMed  Google Scholar 

  19. Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004; 103: 333–339.

    Article  CAS  PubMed  Google Scholar 

  20. Sparrow RL, Williams N . The pattern of HLA-DR and HLA-DQ antigen expression on clonable subpopulations of human myeloid progenitor cells. Blood 1986; 67: 379–384.

    CAS  PubMed  Google Scholar 

  21. Piacibello W, Aglietta M, Stacchini A, Spinelli P, Salvetti L, Kerim S et al. Expression of HLA class II determinants by normal and chronic myeloid leukemia progenitors. Leuk Res 1987; 11: 285–290.

    Article  CAS  PubMed  Google Scholar 

  22. Ottmann OG, Nocka KH, Moore MA, Pelus LM . Differential expression of class II MHC antigens in subpopulations of human hematopoietic progenitor cells. Leukemia 1988; 2: 677–686.

    CAS  PubMed  Google Scholar 

  23. Aglietta M, Piacibello W, Stacchini A, Dezza L, Sanavio F, Malavasi F et al. Expression of HLA class II (DR, DQ) determinants by normal and chronic myeloid leukemia granulocyte/monocyte progenitors. Cancer Res 1986; 46 (Part 1): 1783–1787.

    CAS  PubMed  Google Scholar 

  24. Amatruda 3rd TT, Bohman R, Ranyard J, Koeffler HP . Pattern of expression of HLA-DR and HLA-DQ antigens and mRNA in myeloid differentiation. Blood 1987; 69: 1225–1236.

    CAS  PubMed  Google Scholar 

  25. Diedrichs-Mohring M, Epplen JT, Schendel DJ . Enhanced expression of HLA-class II molecules on activated human T lymphocytes following treatment with tumor necrosis factor alpha. Hum Immunol 1991; 31: 286–292.

    Article  CAS  PubMed  Google Scholar 

  26. Cai J, Terasaki PI, Mao Q, Pham T, El-Awar N, Lee JH et al. Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens. Am J Transplant 2006; 6: 2947–2954.

    Article  CAS  PubMed  Google Scholar 

  27. Rodey GE, Fuller TC . Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol 1987; 7: 229–267.

    CAS  PubMed  Google Scholar 

  28. Rodey GE, Neylan JF, Whelchel JD, Revels KW, Bray RA . Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994; 39: 272–280.

    Article  CAS  PubMed  Google Scholar 

  29. Piazza A, Poggi E, Ozzella G, Borrelli L, Monaco PI, Scornajenghi A et al. Public epitope specificity of HLA class I antibodies induced by a failed kidney transplant: alloantibody characterization by flow cytometric techniques. Transplantation 2006; 81: 1298–1305.

    Article  CAS  PubMed  Google Scholar 

  30. Maruya E, Sasaki N, El-Awar N, Akaza T, Kitawaki J, Saji H et al. Immunogenic HLA class I epitopes identified by humoral response to pregnancies. Clin Transpl 2008, 215–227.

  31. El-Awar N, Terasaki PI, Nguyen A, Sasaki N, Morales-Buenrostro LE, Saji H et al. Epitopes of HLA antibodies found in sera of normal healthy males and cord blood. Clin Transpl 2008, 199–214.

  32. El-Awar N, Terasaki PI, Nguyen A, Sasaki N, Morales-Buenrostro LE, Saji H et al. Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol 2009; 70: 844–853.

    Article  CAS  PubMed  Google Scholar 

  33. Alberu J, Morales-Buenrostro LE, de Leo C, Vargas-Rojas MI, Marino-Vazquez LA, Crispin JC . A non-allogeneic stimulus triggers the production of de novo HLA antibodies in healthy adults. Transpl Immunol 2007; 18: 166–171.

    Article  CAS  PubMed  Google Scholar 

  34. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J . Natural″ human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86: 1111–1115.

    Article  CAS  PubMed  Google Scholar 

  35. Cai J, Terasaki PI, Anderson N, Lachmann N, Schonemann C . Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation 2009; 88: 226–230.

    Article  CAS  PubMed  Google Scholar 

  36. Nagata S, Okano S, Yonemitsu Y, Nakagawa K, Tomita Y, Yoshikai Y et al. Critical roles of memory T cells and antidonor immunoglobulin in rejection of allogeneic bone marrow cells in sensitized recipient mice. Transplantation 2006; 82: 689–698.

    Article  CAS  PubMed  Google Scholar 

  37. Xu H, Chilton PM, Tanner MK, Huang Y, Schanie CL, Dy-Liacco M et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood 2006; 108: 3611–3619.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Taylor PA, Ehrhardt MJ, Roforth MM, Swedin JM, Panoskaltsis-Mortari A, Serody JS et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 2007; 109: 1307–1315.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Storb R . B cells versus T cells as primary barrier to hematopoietic engraftment in allosensitized recipients. Blood 2009; 113: 1205.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Storb R, Floersheim GL, Weiden PL, Graham TC, Kolb HJ, Lerner KG et al. Effect of prior blood transfusions on marrow grafts: abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol 1974; 112: 1508–1516.

    CAS  PubMed  Google Scholar 

  41. Weiden PL, Storb R, Slichter S, Warren RP, Sale GE . Effect of six weekly transfusions on canine marrow grafts: tests for sensitization and abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol 1976; 117: 143–150.

    CAS  PubMed  Google Scholar 

  42. Gutman JA, McKinney SK, Pereira S, Warnock SL, Smith AG, Woolfrey AE et al. Prospective monitoring for alloimmunization in cord blood transplantation: ″virtual crossmatch″ can be used to demonstrate donor-directed antibodies. Transplantation 2009; 87: 415–418.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Takanashi M, Fujiwara K, Tanaka H, Satake M, Nakajima K . The impact of HLA antibodies on engraftment of unrelated cord blood transplants. Transfusion 2008; 48: 791–793.

    Article  PubMed  Google Scholar 

  44. Takanashi M, Atsuta Y, Fujiwara K, Kodo H, Kai S, Sato H et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010; 116: 2839–2846.

    Article  CAS  PubMed  Google Scholar 

  45. Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B, Armand P et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011.

  46. Brunstein CG, Noreen H, Defor TE, Maurer D, Miller JS, Wagner JE . Anti-HLA antibodies in double umbilical cord blood transplantation. Biol Blood Marrow Transplant 2011; 17: 1704–1708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 2009; 88: 1019–1024.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 2012; 47: 508–515.

    Article  CAS  PubMed  Google Scholar 

  49. Kawase T, Matsuo K, Kashiwase K, Inoko H, Saji H, Ogawa S et al. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 2009; 113: 2851–2858.

    Article  CAS  PubMed  Google Scholar 

  50. Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99: 4200–4206.

    Article  CAS  PubMed  Google Scholar 

  51. Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998; 339: 1177–1185.

    Article  CAS  PubMed  Google Scholar 

  52. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104: 1923–1930.

    Article  CAS  PubMed  Google Scholar 

  53. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576–4583.

    Article  CAS  PubMed  Google Scholar 

  54. Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 2010; 115: 2704–2708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P et al. Donor-specific anti-HLA antibodies and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 2011; 118: 5957–5964.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Kataoka K, Yamamoto G, Nannya Y, Yoshimi A, Okada S, Asai T et al. Successful engraftment following HLA-mismatched cord blood transplantation for patients with anti-HLA Abs. Bone Marrow Transplant 2008; 42: 129–130.

    Article  CAS  PubMed  Google Scholar 

  57. Uchiyama M, Ikeda T . Successful engraftment following umbilical cord blood transplantation for patients with HLA antibody with or without corresponding HLA in the transplanted cord blood. Bone Marrow Transplant 2010; 45: 199–200.

    Article  CAS  PubMed  Google Scholar 

  58. Maruta A, Fukawa H, Kanamori H, Harano H, Noguchi T, Kodama F et al. Donor-HLA-incompatible marrow transplantation with an anti-donor cytotoxic antibody in the serum of the patient. Bone Marrow Transplant 1991; 7: 397–400.

    CAS  PubMed  Google Scholar 

  59. Pollack MS, Ririe D . Clinical significance of recipient antibodies to stem cell donor mismatched class I HLA antigens. Hum Immunol 2004; 65: 245–247.

    Article  CAS  PubMed  Google Scholar 

  60. Costa LJ, Moussa O, Bray RA, Stuart RK . Overcoming HLA-DPB1 donor specific antibody-mediated haematopoietic graft failure. Br J Haematol 2010; 151: 94–96.

    Article  PubMed  Google Scholar 

  61. Narimatsu H, Wake A, Miura Y, Tanaka H, Matsumura T, Takagi S et al. Successful engraftment in crossmatch-positive HLA-mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusion. Bone Marrow Transplant 2005; 36: 555–556.

    Article  CAS  PubMed  Google Scholar 

  62. Raghavan R, Jeroudi A, Achkar K, Gaber AO, Patel SJ, Abdellatif A . Bortezomib in kidney transplantation. J Transplant 2010; 2010: Article ID 698594.

  63. Stegall MD, Gloor JM . Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010; 15: 8–10.

    Article  PubMed  Google Scholar 

  64. Knezevic-Maramica I, Kruskall MS . Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43: 1460–1480.

    Article  CAS  PubMed  Google Scholar 

  65. Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T et al. Unmanipulated HLA 2–3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 1073–1084.

    Article  PubMed  Google Scholar 

  66. Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y et al. Unmanipulated HLA 2–3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol 2008; 36: 1–8.

    Article  CAS  PubMed  Google Scholar 

  67. Mizutani K, Terasaki P, Rosen A, Esquenazi V, Miller J, Shih RN et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 2265–2272.

    Article  CAS  PubMed  Google Scholar 

  68. Terasaki PI, Ozawa M, Castro R . Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408–415.

    Article  CAS  PubMed  Google Scholar 

  69. Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH et al. Relapec risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009; 114: 4293–4299.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Lapierre V, Auperin A, Tayebi H, Chabod J, Saas P, Michalet M et al. Increased presence of anti-HLA antibodies early after allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood hematopoietic stem cell transplantation compared with bone marrow transplantation. Blood 2002; 100: 1484–1489.

    Article  CAS  PubMed  Google Scholar 

  71. Nakazawa Y, Saito S, Hasegawa Y, Yanagisawa R, Sakashita K, Kamijo T et al. A possible role for the production of multiple HLA antibodies in fatal platelet transfusion refractoriness after peripheral blood progenitor cell transplantation from the mother in a patient with relapsed leukemia. Transfusion 2007; 47: 326–334.

    Article  CAS  PubMed  Google Scholar 

  72. Hatakeyama N, Hori T, Yamamoto M, Inazawa N, Iesato K, Miyazaki T et al. Platelet transfusion refractoriness attributable to HLA antibodies produced by donor-derived cells after allogeneic bone marrow transplantation from one HLA-antigen-mismatched mother. Pediatr Transplant 2011; 15: E177–E182.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S Yoshihara.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoshihara, S., Taniguchi, K., Ogawa, H. et al. The role of HLA antibodies in allogeneic SCT: is the ‘type-and-screen’ strategy necessary not only for blood type but also for HLA?. Bone Marrow Transplant 47, 1499–1506 (2012). https://doi.org/10.1038/bmt.2011.249

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.249

Keywords

This article is cited by

Search

Quick links